Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)

Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1 therapies pembrolizumab (Merck & Co.) and nivolumab (Bristol Myers Squibb) have become staples in earlier treatment lines, and pembrolizumab is now poised to become the standard of care in the first-line setting in combination with the antibody-drug conjugate (ADC), enfortumab vedotin (Seagen / Pfizer / Astellas), for all patients regardless of platinum sensitivity. The PD-L1 inhibitor avelumab (Merck KGaA / Pfizer) and the PD-1 inhibitor nivolumab, approved as first-line maintenance treatments, highlight the expanded use of immune checkpoint inhibitors in all lines of therapy. In addition, the approvals of ADCs, enfortumab vedotin and trastuzumab deruxtecan (AstraZeneca / Daiichi Sankyo), have diversified the treatment paradigm in later treatment lines. In 2022, nadofaragene firadenovec (Ferring Pharmaceuticals) became the first gene therapy to treat high-risk non-muscle invasive bladder cancer in the United States, and several new therapies with novel combinations and MOAs, anticipated to be approved by 2033, will only intensify the competition in this market.

Questions answered

• What are the sizes of the clinically and commercially relevant drug-treatable populations in this market? How will drug-treatment rates change over time?
• How are bladder cancer and UTUC currently treated, and how do their treatment options differ? What are the key advantages and disadvantages of existing drugs and impact of recent approvals?
• Which emerging therapies are viewed as most promising, and what sales / uptake could they secure in this market?
• What are the key market drivers and constraints, and how will the market evolve over the 10-year forecast period?

Geography: United States, EU5, Japan

Primary research: 19 country-specific interviews with thought-leading urologists and medical oncologists; supported by survey data collected for this and other Clarivate research

Epidemiology: Incidence of bladder cancer and upper tract urothelial carcinoma by country, segmented by clinically and commercially relevant drug-treatable and drug-treated patients

Forecast: 10-year, annualized drug-level sales and patient share of key bladder cancer and upper tract urothelial carcinoma therapies through 2033, segmented by brands / generics / biosimilars and market-relevant drug-treatable populations

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.